Allogene Therapeutics, Inc. (ALLO)
ALLO moved a median of +0.20% 30 minutes after news, and -0.62% by the close. How ALLO actually reacts to news — the realized, point-in-time move the market made, measured across 314 labeled events over the last three years with zero look-ahead.
ALLO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 314 |
| 30-min | +0.20% | 52% | 314 |
| 60-min | +0.28% | 52% | 314 |
| to close | -0.62% | 43% | 312 |
| Middle 50% of ALLO reactions | -1.87% to +2.15% |
|---|---|
| Median reaction (30-min) | +0.20% |
| Measured reactions | 314 |
Half of all Allogene Therapeutics, Inc. news events land between -1.87% and +2.15% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALLO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | +2.67% | 60% | +0.97% |
| Analyst downgrades | 14 | -0.74% | 14% | +0.89% |
| Coverage initiations | 12 | -1.89% | 25% | -3.48% |
| Rating reiterations | 58 | -0.89% | 36% | -0.45% |
| Price-target cuts | 14 | -1.67% | 36% | -0.32% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how ALLO ranks against every other measured name →
That’s how ALLO usually reacts — get an email when it moves on news →Email me when ALLO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALLO's baseline. Nothing else.
Recent ALLO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker | Press release | GlobeNewswire | +2.56% | +1.02% | |
| Form 8-K Allogene Therapeutics, For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +2.56% | +1.02% | |
| Allogene Therapeutics Announces Participation in September Investor Conference | Press release | GlobeNewswire | -0.25% | -0.50% | |
| Form EFFECT Allogene Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.94% | -1.88% | |
| Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | -3.73% | -7.91% | |
| Form 10-Q Allogene Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.73% | -7.91% | |
| Form 8-K Allogene Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -3.73% | -7.91% | |
| Form S-3 Allogene Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -3.73% | -7.91% | |
| Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update | Press release | GlobeNewswire | +0.80% | +1.60% | |
| Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma | Press release | GlobeNewswire | -0.87% | +5.23% | |
| Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors | Press release | GlobeNewswire | -2.41% | +1.60% | |
| Form 8-K Allogene Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.22% | +1.97% | |
| Allogene Therapeutics Announces Planned CEO Succession | Press release | GlobeNewswire | -4.40% | +0.46% | |
| Form 8-K Allogene Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -4.40% | +0.46% | |
| Form DEFA14A Allogene Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -4.40% | +0.46% | |
| Allogene Therapeutics Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.74% | +4.43% | |
| Form DEFA14A Allogene Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.64% | +4.25% | |
| Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | +0.00% | -6.96% | |
| Form 10-Q Allogene Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -6.96% | |
| Form 8-K Allogene Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.96% | |
| Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update | Press release | GlobeNewswire | -0.89% | +3.13% | |
| Form ARS Allogene Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.87% | +2.87% | |
| Form DEF 14A Allogene Therapeutics, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +1.87% | +2.87% | |
| Form DEFA14A Allogene Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.87% | +2.87% | |
| Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia | Press release | GlobeNewswire | -3.51% | -4.13% | |
| Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 | Press release | GlobeNewswire | +2.53% | +2.11% | |
| Form PRE 14A Allogene Therapeutics, For: Apr 20 | SEC filing · Form PRE | SEC EDGAR | -3.51% | -4.13% | |
| Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock | Press release | GlobeNewswire | +0.83% | -0.42% | |
| Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases | Press release | GlobeNewswire | +0.00% | +15.43% | |
| Form 8-K Allogene Therapeutics, For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +6.47% | +5.80% | |
| Allogene Therapeutics Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | +0.00% | +15.43% | |
| Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock | Press release | GlobeNewswire | -9.90% | -24.75% | |
| Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL | Press release | GlobeNewswire | -1.96% | -25.18% | |
| Form 8-K Allogene Therapeutics, For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | -1.96% | -25.18% | |
| Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 | Press release | GlobeNewswire | -1.96% | -25.18% | |
| Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update | Press release | GlobeNewswire | +2.93% | -6.25% | |
| Form 10-K Allogene Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.93% | -6.25% | |
| Form 8-K Allogene Therapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +2.93% | -6.25% | |
| Form S-8 Allogene Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +2.93% | -6.25% | |
| Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update | Press release | GlobeNewswire | -1.42% | +0.76% | |
| Allogene Therapeutics Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.39% | -9.44% | |
| Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T | Press release | GlobeNewswire | +1.01% | +0.68% | |
| Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis | Press release | GlobeNewswire | +0.00% | +1.99% | |
| Allogene Therapeutics Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.03% | -4.07% | |
| Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update | Press release | GlobeNewswire | +3.77% | +12.38% | |
| Form 10-Q Allogene Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.77% | +12.38% | |
| Form 8-K Allogene Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +3.77% | +12.38% | |
| Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting | Press release | GlobeNewswire | -0.40% | -5.60% | |
| Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update | Press release | GlobeNewswire | +2.48% | +0.00% | |
| Form 8-K Allogene Therapeutics, For: Sep 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALLO section they belong to.
Where else ALLO is measured.
ALLO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Dynavax Technologies Corporation (DVAX) | 315 | +0.07% | 55% |
| XOMA Royalty Corporation (XOMA) | 315 | 0.00% | 48% |
| Aptevo Therapeutics Inc. (APVO) | 314 | -0.92% | 33% |
| Myomo Inc. (MYO) | 314 | +0.35% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Allogene Therapeutics, Inc.'s median reaction calculated?
Every labeled ALLO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 314 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of ALLO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ALLO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.